Current Report Filing (8-k)
October 04 2021 - 04:31PM
Edgar (US Regulatory)
0000931059
false
0000931059
2021-09-30
2021-09-30
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT PURSUANT
TO
SECTION 13 or 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): September 30, 2021
Rennova
Health, Inc.
(Exact
Name of Registrant as Specified in Its Charter)
Delaware
(State
or Other Jurisdiction of Incorporation)
001-35141
|
|
68-0370244
|
(Commission
File Number)
|
|
(I.R.S.
Employer Identification No.)
|
400 South Australian Avenue, Suite 800, West
Palm Beach,
Florida
|
|
33401
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
(561)
855-1626
|
(Registrant’s
Telephone Number, Including Area Code)
|
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions (see General Instruction A.2. below):
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered under Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol
|
|
Name of each exchange
on which registered
|
None
|
|
None
|
|
None
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
1.01. Entry into a Material Definitive Agreement.
On
September 30, 2021, Rennova Health, Inc. (the “Company”) completed the second closing of its offering of shares of Series
O Convertible Redeemable Preferred Stock (the “Series O Preferred Stock”). The offering was pursuant to the terms of the
previously-announced Securities Purchase Agreement, dated as of September 7, 2021 (the “Purchase Agreement”), between the
Company and certain existing institutional investors of the Company.
The
Purchase Agreement provided for the issuance of up to 1,100 shares of Series O Preferred Stock. The first closing for 550 shares of Series
O Preferred Stock occurred on September 8, 2021. The Company received proceeds of $500,000 for the second closing and issued an additional
550 shares. The Purchase Agreement restricted the Company’s use of any proceeds of the issuances of the Series O Preferred Stock,
including to payroll and legal and accounting expenses.
The
shares of Series O Preferred Stock were issued in the second closing in reliance on the exemption from registration contained in Section
4(a)(2) of the Securities Act of 1933, as amended, and by Rule 506 of Regulation D promulgated thereunder as a transaction by an issuer
not involving any public offering.
Item
3.02. Unregistered Sales of Equity Securities.
The
information set forth in Item 1.01 is incorporated herein by reference.
Item
8.01 Other Events.
As
a result of conversions of shares of the Company’s preferred stock, the Company had 5,296,350,000
shares of common stock issued and outstanding
as of October 1, 2021.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
October 4, 2021
|
RENNOVA
HEALTH, INC.
|
|
|
|
|
By:
|
/s/
Seamus Lagan
|
|
|
Seamus
Lagan
|
|
|
Chief
Executive Officer
|
|
|
(principal
executive officer)
|
Rennova Health (PK) (USOTC:RNVA)
Historical Stock Chart
From Feb 2024 to Mar 2024
Rennova Health (PK) (USOTC:RNVA)
Historical Stock Chart
From Mar 2023 to Mar 2024